(OSW) OneSpaWorld Holdings - Overview
Stock: Spa Services, Beauty Products, Wellness Classes, Medi-Spa
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.88% |
| Yield on Cost 5y | 1.72% |
| Yield CAGR 5y | 112.50% |
| Payout Consistency | 42.1% |
| Payout Ratio | 22.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 31.2% |
| Relative Tail Risk | -10.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.04 |
| Alpha | -20.79 |
| Character TTM | |
|---|---|
| Beta | 1.376 |
| Beta Downside | 1.150 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.57% |
| CAGR/Max DD | 0.74 |
Description: OSW OneSpaWorld Holdings January 13, 2026
OneSpaWorld Holdings Ltd (NASDAQ: OSW) operates health- and-wellness centers on cruise ships and at destination resorts worldwide, offering a broad menu that includes salon and skin-care services, fitness facilities, pain-management therapies, body-composition analytics, medi-spa treatments (e.g., dermal fillers, IV therapy), and nutrition coaching. The company also sells related products through its timetospa.com e-commerce platform and partners with premium brands such as ELEMIS, Kérastase, CoolSculpting, and Hyperice.
Founded in 2017 and headquartered in Nassau, Bahamas, OSW is classified under the GICS sub-industry “Specialized Consumer Services.” Recent quarterly filings show a 12-month revenue run-rate of roughly $210 million, with an EBITDA margin that has hovered around 15 % despite pandemic-related cruise disruptions. The business is highly sensitive to cruise-passenger volumes-industry forecasts project a 5-7 % annual growth in global cruise capacity through 2028, which should buoy demand for onboard wellness services.
Key sector drivers include rising consumer spending on experiential wellness (U.S. wellness market projected to exceed $1.5 trillion by 2025) and the increasing adoption of premium health-tech services on ships, where average per-guest spend on spa and fitness amenities has risen from $12 in 2020 to $18 in 2023. Monitoring these trends can help gauge OSW’s growth trajectory.
For a data-rich, model-ready view of OSW’s valuation assumptions, you may find ValueRay’s analyst toolkit worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 73.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.87 > 1.0 |
| NWC/Revenue: 7.58% < 20% (prev 7.56%; Δ 0.02% < -1%) |
| CFO/TA 0.11 > 3% & CFO 80.1m > Net Income 73.9m |
| Net Debt (68.2m) to EBITDA (113.3m): 0.60 < 3 |
| Current Ratio: 1.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.1m) vs 12m ago -1.41% < -2% |
| Gross Margin: 15.36% > 18% (prev 0.14%; Δ 1522 % > 0.5%) |
| Asset Turnover: 127.7% > 50% (prev 118.9%; Δ 8.77% > 0%) |
| Interest Coverage Ratio: 8.08 > 6 (EBITDA TTM 113.3m / Interest Expense TTM 10.9m) |
Altman Z'' -1.16
| A: 0.10 (Total Current Assets 155.3m - Total Current Liabilities 84.3m) / Total Assets 732.6m |
| B: -0.35 (Retained Earnings -252.8m / Total Assets 732.6m) |
| C: 0.12 (EBIT TTM 88.3m / Avg Total Assets 733.3m) |
| D: -1.41 (Book Value of Equity -253.4m / Total Liabilities 179.8m) |
| Altman-Z'' Score: -1.16 = CCC |
Beneish M -3.05
| DSRI: 1.06 (Receivables 47.9m/42.2m, Revenue 936.1m/872.6m) |
| GMI: 0.89 (GM 15.36% / 13.63%) |
| AQI: 0.97 (AQ_t 0.74 / AQ_t-1 0.76) |
| SGI: 1.07 (Revenue 936.1m / 872.6m) |
| TATA: -0.01 (NI 73.9m - CFO 80.1m) / TA 732.6m) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of OSW shares?
Over the past week, the price has changed by +8.24%, over one month by -1.80%, over three months by -3.21% and over the past year by -1.75%.
Is OSW a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OSW price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.3 | 18.7% |
| Analysts Target Price | 25.3 | 18.7% |
| ValueRay Target Price | 24.2 | 13.6% |
OSW Fundamental Data Overview February 03, 2026
P/E Forward = 27.8552
P/S = 2.1558
P/B = 3.6241
Revenue TTM = 936.1m USD
EBIT TTM = 88.3m USD
EBITDA TTM = 113.3m USD
Long Term Debt = 85.2m USD (from longTermDebt, last quarter)
Short Term Debt = 2.43m USD (from shortTermDebt, last quarter)
Debt = 97.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 68.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.09b USD (2.02b + Debt 97.7m - CCE 29.6m)
Interest Coverage Ratio = 8.08 (Ebit TTM 88.3m / Interest Expense TTM 10.9m)
EV/FCF = 31.24x (Enterprise Value 2.09b / FCF TTM 66.8m)
FCF Yield = 3.20% (FCF TTM 66.8m / Enterprise Value 2.09b)
FCF Margin = 7.13% (FCF TTM 66.8m / Revenue TTM 936.1m)
Net Margin = 7.90% (Net Income TTM 73.9m / Revenue TTM 936.1m)
Gross Margin = 15.36% ((Revenue TTM 936.1m - Cost of Revenue TTM 792.3m) / Revenue TTM)
Gross Margin QoQ = 15.26% (prev 12.97%)
Tobins Q-Ratio = 2.85 (Enterprise Value 2.09b / Total Assets 732.6m)
Interest Expense / Debt = 6.38% (Interest Expense 6.24m / Debt 97.7m)
Taxrate = 2.32% (578.0k / 24.9m)
NOPAT = 86.2m (EBIT 88.3m * (1 - 2.32%))
Current Ratio = 1.84 (Total Current Assets 155.3m / Total Current Liabilities 84.3m)
Debt / Equity = 0.18 (Debt 97.7m / totalStockholderEquity, last quarter 552.8m)
Debt / EBITDA = 0.60 (Net Debt 68.2m / EBITDA 113.3m)
Debt / FCF = 1.02 (Net Debt 68.2m / FCF TTM 66.8m)
Total Stockholder Equity = 546.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.08% (Net Income 73.9m / Total Assets 732.6m)
RoE = 13.53% (Net Income TTM 73.9m / Total Stockholder Equity 546.5m)
RoCE = 13.98% (EBIT 88.3m / Capital Employed (Equity 546.5m + L.T.Debt 85.2m))
RoIC = 13.46% (NOPAT 86.2m / Invested Capital 640.9m)
WACC = 10.77% (E(2.02b)/V(2.12b) * Re(10.99%) + D(97.7m)/V(2.12b) * Rd(6.38%) * (1-Tc(0.02)))
Discount Rate = 10.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.91%
[DCF Debug] Terminal Value 70.74% ; FCFF base≈69.4m ; Y1≈77.9m ; Y5≈104.0m
Fair Price DCF = 10.64 (EV 1.15b - Net Debt 68.2m = Equity 1.08b / Shares 102.0m; r=10.77% [WACC]; 5y FCF grow 14.27% → 2.90% )
EPS Correlation: 51.61 | EPS CAGR: 31.15% | SUE: -4.0 | # QB: 0
Revenue Correlation: 85.85 | Revenue CAGR: 34.26% | SUE: -0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=-0.001 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=1.14 | Chg30d=-0.024 | Revisions Net=-3 | Growth EPS=+12.6% | Growth Revenue=+7.0%